Fig. 2: Antiviral activity of VHH60.
From: A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug
a VHH60 inhibits pseudovirus carrying wildtype spike protein infection on Caco-2 cell line. b VHH60 inhibits ancestral SARS-CoV-2 infection on Vero-E6. c Survival curve of mice infected by SARS-CoV-2. Vehicle group all died at 4 d.p.i (5/5), one in VHH60 group (1/5) died. d Body weight change of mice infected by SARS-CoV-2. Data is represented as ratio of body weights at indicated timepoint versus day 0 (n = 10 at 0 and 3 d.p.i, n = 4 at 4 d.p.i, n = 5 at 5.d.p.i). e Virus load in lung after 3 days of infection (n = 5). f Representative image of immunofluorescence from lung. Blue: Nuclei, Red: ACE2, Green: nucleocapsid protein (NP). g Representative image of hematoxylin-eosin (H&E) staining from the lung. Scar bar, 2000 μm in the up row, 150 μm in the down row. One-way ANOVA with Tukey’s multiple comparison test was used. *P < 0.05. Error bars represent the means with SDs.
